Tag: genomics
-
Commentary – Scott Gottlieb’s Legacy
During his tenure, FDA issued a number of guidance documents outlining regulatory processes and practices that streamline reviews, yet are still dictated by scientific evidence.
-
Sequencing IDs Pancreatic Cancer Targets
A genomic analysis of tumor samples from patients with pancreatic cancer, a cancer with a typically poor outlook, identified targets for early precision cancer detection and treatments.
-
Biogen Acquires Gene Therapy Company in $800M Deal
A company developing treatments for inherited eye diseases that replace malfunctioning with healthy genes is being acquired by biotechnology company Biogen.
-
Blood Test as Good as Biopsy to Detect Cancer Targets
Results of a clinical trial show a commercial blood test works at least as well as tissue biopsies for determining precise genetic mutations causing most lung cancers.
-
Anti-Inflammatory Human Protein Produced in Plants
Researchers in Canada genetically engineered tobacco plants to economically produce large quantities of a human protein with anti-inflammatory properties.
-
Trials Underway Testing Crispr for Blood Disorders
Clinical trials testing the genome editing technique Crispr for sickle cell disease and beta thalassemia, two inherited blood disorders, enrolled and infused their first patients.
-
Gene Editing Deactivates Cause of T-Cell Side Effects
A biotechnology company developing engineered T-cells as treatments for cancer, used gene editing to deactivate a likely cause of serious adverse effects from its therapies.
-
Gene Therapy Company Acquired in $4.3B Deal
Spark Therapeutics, a biotechnology company that pioneered gene therapies, is being acquired by drug maker Roche Group in a deal valued at $4.3 billion.
-
Trial Shows RNA Therapy Safe for Diabetes
Results from a clinical trial show a new drug with synthetic messenger RNA is safe for people with diabetes, and has the potential to promote new blood vessel growth.
-
High-Speed Screens, A.I., Boost Nanoscale Medicines
Biomedical engineers are using high-throughput screening techniques and machine learning to speed and improve the design of new drugs based on nanoscale particles.